TABLE 1.

P-gp inhibition by derivatives 4, 20, 21, 22, and 23 in the human NSCLC MDR cancer cell line.

Treatments	MFI a	FAR b	SI c
NCI-H460 control	134.10
NCI-H460/R control	16.96		12.65
DexVER	36.07	2.13	26.90
4 d	28.97	1.71	21.60
20	23.71	1.40	17.68
21	19.48	1.15	14.53
22	18.25	1.08	13.61
23 d	35.54	2.10	26.50

^aThe measured mean fluorescence intensity (MFI) was used for the calculation of the fluorescence activity ratio (FAR).

^bvia the following equation: FAR = MFI_{MDR treated}/MFI_{MDR control}. FAR values above 1.50 indicate P-gp inhibition.

^cThe sensitivity index (SI) was calculated on the basis of the measured mean fluorescence intensity (MFI) expressed via the following equation: SI = (MFI_{MDR treated} * 100)/MFI_{sensitive control}. SI values above 20 account for P-gp inhibition.

^dResults published in Isca et al. (2020).

Sensitive cancer cell line and its MDR counterpart used in the study: non-small cell lung carcinoma-NSCLC (NCI-H460 and NCI-H460/R).

DexVER was applied at the same concentration (20 µM) as tested derivatives.